CMXHF
CSL Limited OTC$91.14
Mkt Cap $44.2B
52w Low $86.84
4.4% of range
52w High $184.09
50d MA $97.51
200d MA $123.34
P/E (TTM)
14.0x
EV/EBITDA
17.2x
P/B
2.0x
Debt/Equity
0.6x
ROE
7.3%
P/FCF
31.0x
RSI (14)
—
ATR (14)
—
Beta
0.22
50d MA
$97.51
200d MA
$123.34
Avg Volume
4.2K
About
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunod…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 10, 2026 | AMC | 4.14 | 4.03 | -2.7% | 125.60 | -12.0% | -4.7% | -11.3% | -18.4% | -17.7% | -17.7% | — |
| Aug 18, 2025 | AMC | 2.62 | 1.38 | -47.3% | 179.00 | -22.2% | -21.8% | -17.3% | -15.7% | -17.2% | -18.7% | — |
| Feb 11, 2025 | AMC | 4.41 | 2.56 | -42.0% | 161.00 | -2.8% | -3.5% | +2.0% | -3.0% | -0.2% | +1.9% | — |
| Aug 13, 2024 | AMC | 1.80 | 1.83 | +1.7% | 197.05 | -2.1% | -2.0% | -1.5% | -2.0% | +3.5% | +0.2% | — |
| Apr 11, 2024 | AMC | 4.07 | 2.78 | -31.7% | 180.75 | +0.0% | +0.0% | +0.0% | -3.2% | -4.5% | -4.1% | — |
| Jun 30, 2023 | AMC | 1.67 | 0.82 | -51.1% | 187.30 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -5.9% | — |
| Dec 30, 2022 | AMC | 3.50 | 2.36 | -32.6% | 195.06 | -5.0% | -4.5% | -0.2% | -0.2% | -0.2% | -2.1% | — |
| Jun 30, 2022 | AMC | 1.09 | 0.63 | -42.3% | 184.00 | -0.1% | -0.1% | +1.8% | +5.3% | +7.5% | +6.2% | — |
| Dec 30, 2021 | AMC | 3.40 | 2.76 | -18.8% | 217.50 | -1.6% | -1.7% | -1.7% | -3.4% | -3.4% | -9.4% | — |
| Jun 30, 2021 | AMC | 1.09 | 0.61 | -43.9% | 218.31 | -3.9% | -3.9% | -1.9% | -4.2% | -3.5% | -7.0% | — |
Data updated apr 28, 2026 5:27am
· Source: massive.com